Changes in CHK2 function could also affect the efficacy of other agents used for NHL treatment (e.g., cyclophosphamide), since CHK2 is a member of a pathway executing response to DNA-damaging agents in general [45]. This evidence concerns the gene CHEK2 and non-Hodgkin lymphoma.